01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO Plc – £6.3M HRV CONTRACT SIGNED WITH BIOTECH CLIENT January 2, 2024 – Posted in: hVIVO (HVO)

Highlights ·    Study to enter hVIVO’s state-of-the-art Canary Wharf quarantine facilities in H2 2024 ·    Potential to enhance value of the client’s antiviral by generating efficacy data in HRV   hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV –…

Continue reading

#HVO hVIVO PLC- £13.6m RSV antiviral contract November 10, 2022 – Posted in: Open Orphan (ORPH)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus (“RSV”) antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model                                 The Phase 2a double-blinded placebo-controlled human challenge trial will take place at…

Continue reading

#ORPH Open Orphan – Vaccine field study contract May 5, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase II field study of the client’s respiratory syncytial virus (RSV) vaccine candidate.   As part of the study, hVIVO will…

Continue reading

#ORPH Open Orphan Plc – Positive results from Flu Human Challenge Study December 6, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH) a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, notes the announcement released from SAB Biotherapeutics (NASDAQ: SABS) (“SAB”), reporting positive results from a human challenge study testing SAB-176, its investigational therapeutic for the treatment of seasonal influenza. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a randomised, double-blinded, placebo-controlled study using its Influenza Human Challenge Study Model. The trial evaluated…

Continue reading